Literature DB >> 11502811

Diagnostic accuracy of 18F-fluorodeoxyglucose positron emission tomography in the follow-up of papillary or follicular thyroid cancer.

L Hooft1, O S Hoekstra, W Devillé, P Lips, G J Teule, M Boers, M W van Tulder.   

Abstract

Positron emission tomography with 18F-fluorodeoxyglucose is a relatively new nuclear imaging technique in oncology. We conducted a systematic review to determine the diagnostic accuracy of 18F-fluorodeoxyglucose positron emission tomography in patients suspected of recurrent papillary or follicular thyroid carcinoma. Two reviewers independently selected, extracted, and assessed data from relevant literature found in computerized databases and by reference tracking. Prospective and retrospective studies with 10 human subjects, or more, that evaluated the accuracy of ring positron emission tomography, using 18F-fluorodeoxyglucose in follicular and papillary thyroid cancer, were included. Studies on 18F-fluorodeoxyglucose imaging using gamma cameras, reviews, case reports, editorials, letters, and comments were excluded. The methodological quality was assessed by applying the criteria for diagnostic tests recommended by the Cochrane Methods Group on Screening and Diagnostic Tests. A rating system was used for qualitative analysis consisting of four levels of evidence (1 = highest level; 4 = lowest level). Fourteen studies met the inclusion criteria. All studies claimed a positive role for positron emission tomography but, at evidence levels 3 or 4, precluding quantitative analysis. Methodological problems included poor validity of reference tests and a lack of blinding of test performance and interpretation. The reviewed material was heterogeneous with respect to patient variation and validation methodology. The most consistent data were found on the ability of 18F-fluorodeoxyglucose positron emission tomography to provide an anatomical substrate in patients with elevated serum Tg and negative iodine-131 scans. In conclusion, the results seem to support the potential of 18F-fluorodeoxyglucose positron emission tomography to identify and localize foci of recurrent cancer in the latter patient subset. However, implementation of positron emission tomography in a routine diagnostic algorithm requires additional evidence.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11502811     DOI: 10.1210/jcem.86.8.7777

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  10 in total

Review 1.  Papillary thyroid cancer: medical management and follow-up.

Authors:  Richard T Kloos
Journal:  Curr Treat Options Oncol       Date:  2005-07

2.  Short-term outcome of differentiated thyroid cancer patients receiving a second iodine-131 therapy on the basis of a detectable serum thyroglobulin level after initial treatment.

Authors:  Leonardo Pace; Michele Klain; Carmine Albanese; Barbara Salvatore; Giovanni Storto; Andrea Soricelli; Marco Salvatore
Journal:  Eur J Nucl Med Mol Imaging       Date:  2005-10-05       Impact factor: 9.236

3.  Two Distant Muscular Metastases from Papillary Carcinoma of the Thyroid Demonstrated by (18)F-FDG PET/CT and Confirmed by Biopsy.

Authors:  Federico Caobelli; Barbara Paghera; Maria Beatrice Panarotto; Luca Camoni; Raffaele Giubbini
Journal:  Nucl Med Mol Imaging       Date:  2011-10-08

4.  Value of (124)I-PET/CT in staging of patients with differentiated thyroid cancer.

Authors:  L S Freudenberg; G Antoch; W Jentzen; R Pink; J Knust; R Görges; S P Müller; A Bockisch; J F Debatin; W Brandau
Journal:  Eur Radiol       Date:  2004-06-30       Impact factor: 5.315

5.  Combined PET/CT with iodine-124 in diagnosis of spread metastatic thyroid carcinoma: a case report.

Authors:  L S Freudenberg; G Antoch; R Görges; J Knust; R Pink; W Jentzen; J F Debatin; W Brandau; A Bockisch; J Stattaus
Journal:  Eur Radiol       Date:  2003-12       Impact factor: 5.315

Review 6.  Sodium iodide symporter and the radioiodine treatment of thyroid carcinoma.

Authors:  June-Key Chung; Hye Won Youn; Joo Hyun Kang; Ho Young Lee; Keon Wook Kang
Journal:  Nucl Med Mol Imaging       Date:  2010-02-26

7.  Prospective comparison of two gamma probes for intraoperative detection of 18F-FDG: in vitro assessment and clinical evaluation in differentiated thyroid cancer patients with iodine-negative recurrence.

Authors:  Chantal Curtet; Thomas Carlier; Eric Mirallié; Caroline Bodet-Milin; Caroline Rousseau; Jacques Barbet; Francoise Kraeber-Bodéré
Journal:  Eur J Nucl Med Mol Imaging       Date:  2007-05-24       Impact factor: 9.236

8.  [18F]-FDG-PET/CT and [18F]-FAZA-PET/CT Hypoxia Imaging of Metastatic Thyroid Cancer: Association with Short-Term Progression After Radioiodine Therapy.

Authors:  Masatoyo Nakajo; Megumi Jinguji; Atsushi Tani; Yoriko Kajiya; Tooru Nandate; Ikumi Kitazano; Takashi Yoshiura
Journal:  Mol Imaging Biol       Date:  2020-12       Impact factor: 3.488

9.  Differentiated thyroid cancer: management of patients with radioiodine nonresponsive disease.

Authors:  Naifa Lamki Busaidy; Maria E Cabanillas
Journal:  J Thyroid Res       Date:  2012-02-28

10.  Evaluation of CYFRA 21.1 as a Dedifferentiation Marker of Advanced Thyroid Cancer.

Authors:  Sumeet Suresh Malapure; Chetan D Patel; R Lakshmy; Chandrashekhar Bal
Journal:  Indian J Nucl Med       Date:  2020-03-12
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.